Search - tctmd.com

Displaying 461 - 480 of 649

Sort: Relevancy | Date

Presentation TCT 2016

Update on Epidemiology, Prevention, Screening, and Control

Presenter: Habib Gamra, Ahmed Suliman, Bernard J. Gersh

November 01, 2016

Presentation TCT 2016

Delivery System and Therapeutic Challenges and Opportunities in Africa

Presenter: Graham A. Cassel, Harun A Otieno

November 01, 2016

Presentation TCT 2016

PCI of Non-Culprit Lesions in STEMI: Take-home Messages

Presenter: Graham A. Cassel

October 31, 2016

Presentation TCT 2016

PCI of Non-Culprit Lesions in STEMI: Flaws in the Previous Trials

Presenter: Graham A. Cassel, Nick Curzen

October 31, 2016

Presentation TCT 2016

PCI of Non-Culprit Lesion in STEMI: Literature Review

Presenter: Graham A. Cassel, Margaret B. McEntegart

October 31, 2016

Presentation TCT 2016

Case #2: STEMI in Patient With Left Main and Multivessel Disease

Presenter: Graham A. Cassel, Narek Zakaryan

October 31, 2016

Presentation TCT 2016

Case #1: STEMI in Patient With Moderate Bystander Disease

Presenter: Graham A. Cassel, Sergey A. Abugov

October 31, 2016

Presentation TCT 2016

Introduction: PCI of Non-Culprit Lesions in STEMI

Presenter: Graham A. Cassel

October 31, 2016

Presentation TCT 2016

Case Resolution: How Did We Treat this Patient?

Presenter: Nick Curzen, Michael Mahmoudi

October 31, 2016

Presentation TCT 2016

TAVR Restenosis: Review of the Literature

Presenter: Nick Curzen

October 31, 2016

Presentation TCT 2016

Case Introduction: An 87 Year Old Woman With Recurrent Dyspnea 7 Years After TAVR

Presenter: Nick Curzen, Michael Mahmoudi

October 31, 2016

Presentation TCT 2016

TAVR for Intermediate-Risk and Low-Risk Patients: Review of the Literature

Presenter: Niall T. Mulvihill, Michael Mahmoudi

October 31, 2016

Presentation TCT 2016

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Con Position

Presenter: Niall T. Mulvihill, Hellmuth Weich

October 31, 2016

Presentation TCT 2016

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Pro Position

Presenter: Niall T. Mulvihill, Antoniette Neylon

October 31, 2016

Presentation TCT 2016

Introduction: TAVR in Intermediate-Risk and Low-Risk With Severe Aortic Stenosis

Presenter: Niall T. Mulvihill

October 31, 2016

News Daily News

The Good, the Bad, and the Ugly: PCI Public Reporting Needs Fine-tuning, Says SCAI

Todd Neale

October 20, 2016

News Opinion Fellow Talk

Top 10 Tricks for Transradial Procedures

October 10, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Daily News

Las Pruebas Genéticas No son Necesariamente la Prueba Concluyente en el Diagnóstico de la CMH

Yael L. Maxwell

August 23, 2016

News Daily News

Genetic Testing Not Necessarily the Nail in the Coffin for HCM Diagnosis

Yael L. Maxwell

August 23, 2016

Advertisement

Update on Epidemiology, Prevention, Screening, and Control

Delivery System and Therapeutic Challenges and Opportunities in Africa

PCI of Non-Culprit Lesions in STEMI: Take-home Messages

PCI of Non-Culprit Lesions in STEMI: Flaws in the Previous Trials

PCI of Non-Culprit Lesion in STEMI: Literature Review

Case #2: STEMI in Patient With Left Main and Multivessel Disease

Case #1: STEMI in Patient With Moderate Bystander Disease

Introduction: PCI of Non-Culprit Lesions in STEMI

Case Resolution: How Did We Treat this Patient?

TAVR Restenosis: Review of the Literature

Case Introduction: An 87 Year Old Woman With Recurrent Dyspnea 7 Years After TAVR

TAVR for Intermediate-Risk and Low-Risk Patients: Review of the Literature

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Con Position

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Pro Position

Introduction: TAVR in Intermediate-Risk and Low-Risk With Severe Aortic Stenosis

The Good, the Bad, and the Ugly: PCI Public Reporting Needs Fine-tuning, Says SCAI

Top 10 Tricks for Transradial Procedures

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Las Pruebas Genéticas No son Necesariamente la Prueba Concluyente en el Diagnóstico de la CMH

Genetic Testing Not Necessarily the Nail in the Coffin for HCM Diagnosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content